Skip to main content

Advertisement

Table 1 Baseline characteristics of patients

From: A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

   Clarithromycin group (N = 27) Placebo group (N = 31)
Variable
 Age (years) Median (IQR) 63 (55.0–66.5) 63 (55.5–66.0)
 Male sex No. (%) 20 (74.1%) 20 (64.5%)
 Type of myeloma No. (%)   
  IgA   3 (11.1%) 9 (29.0%)
  IgG   20 (74.1%) 17 (54.8%)
  Light chain   4 (14.8%) 5 (16.1%)
 International staging system No. (%)   
  I   7 (%) (25.9%) 9 (29.0%)
  II   10 (%) (37.0%) 17 (54.8%)
  III   9 (33.1%) 4 (12.9%)
  Missing   1 (3.8%) 1 (3.2%)
 Cytogenetic features No. (%)   
  Standard risk   18 (66.7%) 18 (58.1%)
  High riska   6 (22.2%) 8 (25.8%)
  Data not available   3 (11.1%) 5 (16.1%)
 WHO performance status No. (%)   
  0   14 (51.9%) 17 (54.8%)
  ≥ 1   13 (48.1%) 14 (45.2%)
 Serum creatinine ≥ 130 µmol/L No. (%) 5 (18.5%) 2 (6.5%)
 Serum LDH ≥ 260 U/L No. (%) 1 (3.7%) 4 (12.9%)
 Serum C-reactive protein ≥ 8 mg/L No. (%) 9 (33.3%) 9 (29.0%)
  1. IQR interquartile range, LDH lactate dehydrogenase
  2. at(4;14), t(14;16), t(14;20) or del(17p)